Clinical Evaluation of Basal-Bolus Therapy Delivered by the V-Go® Wearable Insulin Delivery Device in Patients with Type 2 Diabetes: A Retrospective Analysis
| Autor: | Trisha Zeidan, Aleda M.H. Chen, Carla Nikkel, Stephanie Wu, Beth Dziengelewski |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
insulin endocrine system diseases medicine.medical_treatment Population lcsh:RS1-441 030209 endocrinology & metabolism Type 2 diabetes Hypoglycemia lcsh:Pharmacy and materia medica 03 medical and health sciences V-Go 0302 clinical medicine Internal medicine Medicine Pharmacology (medical) In patient 030212 general & internal medicine General Pharmacology Toxicology and Pharmaceutics education hemoglobin A1c Glycemic education.field_of_study business.industry Insulin nutritional and metabolic diseases medicine.disease Regimen glycemic control Insulin delivery device type 2 diabetes business |
| Zdroj: | Pharmacy Volume 8 Issue 4 Pharmacy, Vol 8, Iss 215, p 215 (2020) |
| ISSN: | 2226-4787 |
| DOI: | 10.3390/pharmacy8040215 |
| Popis: | Insulin therapy is frequently required to achieve glycemic targets (A1c) in type 2 diabetes (T2D) however, clinicians and patients face barriers with the complexities of multiple daily injection regimens. Patch-like wearable insulin devices, such as V-Go, may simplify and optimize this complexity. This study evaluated the change in A1C and insulin total daily dose (TDD) in a suboptimally-controlled (not achieving A1C targets) T2D population after switching to V-Go. A retrospective chart analysis at a diabetes clinic was performed to evaluate change in A1c measurements from baseline (V-Go initiation) to end of study observation. Of the 139 patients enrolled, A1C significantly decreased from baseline (&minus 1.5 ± 1.79% p < 0.001). Patients prescribed insulin at baseline (n = 122) used significantly less insulin TDD (&minus 8 u/day p = 0.006). The percentage of patients meeting the target of A1C < 8% increased from 14% at baseline to 48% at study completion (p = 0.008). Patients prescribed a basal-bolus regimen prior to V-Go achieved an A1C reduction of 1.5 ± 2.0% (p < 0.0001) and experienced the greatest reduction in TDD (&minus 24 u/day 0.0001). Thus, patients switching to V-Go from a variety of therapies at baseline experienced reductions in A1C while using less insulin, with a reduction in clinically relevant hypoglycemia, indicating the potential benefit of V-Go in optimizing and simplifying T2D care. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|